Agape Compounds Research Library

  • F-Words Faith Series: Faith

    Adopted from 10 F-Words for the Faith-Driven Entrepreneur by Roland Heersink

    FAITH – Part 1 of 10

    Hebrews 11:1 puts it simply: faith is the substance of things hoped for, the evidence of things not seen. I didn’t fully understand that verse until I was building something with no guarantee it would work.

    Starting Agape wasn’t a calculated bet with the odds stacked in my favor. It was building a company in a regulatory gray zone, in an industry most people don’t understand, with a supply chain, payment processors, and compliance requirements that changed under our feet more than once. There was no spreadsheet that could prove this would work. At some point, the only thing left to do was build anyway.

    That’s what faith actually looks like in practice, not the absence of doubt, but moving forward while the doubt is still there.

    What faith isn’t

    It’s not recklessness. We didn’t skip due diligence because we “trusted God would work it out.” We spent months vetting testing labs, reviewing legal opinions, and rebuilding pricing models from scratch when we found errors. Faith didn’t replace the work, it’s what got me back to the desk the next morning after a deal fell through or a processor said no.

    What faith is

    It’s the decision to keep building something true, even when the fastest path forward would have meant cutting corners. Every COA we publish, every testing panel we run, every honest “here’s what we don’t know yet” moment on this site — that’s faith made practical. “Restored by Love. Fortified for Life” isn’t just a tagline; it’s the same principle Hebrews describes: conviction acted on before the proof arrives.

    Where this series is headed

    Faith is the foundation, but it’s not the whole picture. Over the next nine posts, we’ll walk through the rest — Failure, Fear, Focus, Finances, and more, each one a real piece of what it actually took to build this. Not polished hindsight. The parts that were hard while they were happening.

    If you’re building something of your own right now, wherever you are in that process: the substance of things hoped for is still substance, even when you can’t see the finish line yet.

    This series shares personal reflections on faith and entrepreneurship. It is not medical, financial, or business advice, and reflects one founder’s perspective and experience.

  • Behind the Science: How We Verify Every Batch

    “Trust us” isn’t a testing methodology. So here’s exactly what happens before any compound reaches you — not a summary, the actual panel.

    The testing panel

    Every batch goes through independent third-party testing at Purity Analytics, a Georgia-based lab, covering:

    • HPLC (High-Performance Liquid Chromatography) — measures purity, confirming what percentage of the vial is actually the compound it claims to be
    • Mass spectrometry — confirms molecular identity, verifying the compound is what it says it is, not just how pure it is
    • Heavy metals (ICP-MS) — screens for contamination from the manufacturing process
    • TAMC/TYMC — total aerobic microbial count and total yeast/mold count, catching biological contamination
    • Endotoxin testing (LAL) — screens for bacterial endotoxins, especially critical for injectable research compounds

    Why the signature matters more than the number

    A COA is only as trustworthy as its origin. Ours are cryptographically signed using PKCS#7/Sectigo digital signatures — the same underlying technology banks use to verify document authenticity. That means the document itself can prove it hasn’t been altered since the lab issued it, and you can verify that signature yourself in Adobe Acrobat, not just take our description of it on faith.

    Every COA is also independently checkable at verify.purityanalytics.com — you don’t need to trust our website’s claim that testing happened; you can go straight to the lab’s own verification system.

    The honest part

    This process isn’t unique to us, it’s what any legitimate research supplier should be doing. What we think is actually worth pointing out: it’s rare to see suppliers publish the full panel rather than a vague “tested for purity” claim. See our [Research Index] for the published literature these compounds are studied against, and check any batch’s COA yourself before you use it.

    This content is provided for research and informational purposes only. Agape Compounds products are not intended for human or animal consumption.

  • Peptide of the Week: BPC-157

    If you’ve spent any time researching peptides, you’ve run into BPC-157. It’s the most talked-about compound in the space — and also one of the most commonly oversimplified.

    What it is

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein naturally found in human gastric juice. That origin is part of why it’s drawn so much research interest: the native protein appears to play a role in protecting and repairing the stomach lining, and researchers have spent years investigating whether a stable, synthetic version could extend that protective effect elsewhere in the body.

    What researchers study

    • Tissue repair mechanisms in tendons, ligaments, and muscle in animal models
    • Angiogenesis (new blood vessel formation) as a proposed pathway behind its repair effects
    • Gut barrier integrity and gastrointestinal protection — its original research context
    • Interaction with growth factor signaling pathways involved in wound healing
    • These findings are drawn from Chang et al. (2011, Journal of Applied Physiology), Seiwerth et al. (2021, Frontiers in Pharmacology), and Sikiric et al. (2003, Inflammopharmacology) — full citation trail on our [Research Index].

    Where the regulatory conversation stands right now

    This is worth being direct about, since it changes week to week. BPC-157 has no FDA-approved drug application and never has — that’s not new. What’s new: it spent 2023–2026 in the FDA’s Category 2 (identified safety concern) for compounding pharmacies, was removed from that category in April 2026, and was reviewed again by the FDA’s advisory committee just this past July for possible inclusion on the permitted compounding list. As of today, that decision hasn’t been finalized. BPC-157 sits in a genuine in-between: no longer flagged as an active concern, not yet formally cleared either. We’ll update this if that changes.

    Where to go next

    BPC-157 shows up across three of our topic guides, each covering a different angle of the research: [Building Muscle], [Longevity], and [Immunity]. Start with [What Are Peptides?] if you’re new here.

    This content is provided for research and informational purposes only. Agape Compounds products are not intended for human or animal consumption.